

Supplementary Table S2: Independent prognostic factors in 457 patients according to <i>RAS</i> and <i>BRAF</i> mutation status and pretreatment clinical characteristics (Cox model)									
	Progression-free survival			Overall survival			Overall survival Censored at start 2nd or 3rd line anti-EGFR therapy		
	HR	(95% CI)	P	HR	95% CI	P	HR	95% CI	P
<i>RAS/BRAF</i> wild-type	1			1			1		
<i>RAS</i> mutation	1.38	(1.12 - 1.70)	0.003	1.32	1.08 - 1.63	0.008	1.38	1.09 - 1.74	0.007
<i>BRAF</i> mutation	2.66	(1.94 - 3.64)	<0.001	3.23	2.36 - 4.41	<0.001	3.62	2.59 - 5.07	<0.001
WHO PS 0	1			1			1		
WHO PS 1	1.49	(1.20 - 1.85)	<0.001	1.64	1.32 - 2.04	<0.001	1.82	1.43 - 2.31	<0.001
WHO PS 2	1.95	(1.21 - 3.15)	0.006	3.48	2.18 - 5.57	<0.001	4.06	2.52 - 6.53	<0.001
ALP level normal	1			1			1		
ALP level elevated	1.41	(1.16 - 1.73)	0.001	1.91	1.57 - 2.34	<0.001	1.95	1.55 - 2.44	<0.001

Abbreviations: HR, Hazard ratio; CI, Confidence interval; PS, Performance status; ALP, Alkaline phosphatase